CAR-NK-92MI and CAR-CD19-T cells targeting CD19 antigen exhibit significant in vitro killing activity on mantle cell lymphoma / 中国肿瘤生物治疗杂志
Chinese Journal of Cancer Biotherapy
; (6): 455-461, 2018.
Article
em Zh
| WPRIM
| ID: wpr-821247
Biblioteca responsável:
WPRO
ABSTRACT
@#[Abstract] Objective: To investigate the in vitro cytotoxicity of the chimeric antigen receptor-modified T cells and NK-92MI cells (CAR-NK-92MI cells) and CAR-CD19-T cells against mantle cell lymphoma (MCL). Methods: CAR-T cell technology, successfully obtained in clinical trial of B-lineage acute lymphoblastic leukemia (B-ALL) treatment, was used in this study. In the case of high expression of CD19 antigen in MCL, CAR- CD19-T cells and CAR- CD19-NK-92MI cells targeting CD19 antigen were generated, respectively. Then, their cytotoxicity against MCL cell lines was detected by LDH release assay and the results were verified by flow cytometry. Results: Compared with control group, both CAR-NK-92MI and CAR-CD19-T cells exhibited prominent killing effect against MCLcells(all P<0.01); in addition, the two CAR cells exhibited high cytotoxicity against K562-CD19 cells but not on K562 cells(all P <0.01). The death rate of MCL cells from CAR-NK-92MI group was 30%-40% more than that of control group, and the death rate of MCL from CAR-CD19-T group was 40%-50% more than that of control group. Conclusion: Both CAR-NK-92MI and CAR-CD19-T cells exhibited potent cytotoxicity against MCLcells in vitro.
Texto completo:
1
Índice:
WPRIM
Tipo de estudo:
Clinical_trials
Idioma:
Zh
Revista:
Chinese Journal of Cancer Biotherapy
Ano de publicação:
2018
Tipo de documento:
Article